Ken Griffin Lantern Pharma Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 39,800 shares of LTRN stock, worth $140,892. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,800
Previous 42,800
7.01%
Holding current value
$140,892
Previous $199,000
26.63%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding LTRN
# of Institutions
34Shares Held
1.29MCall Options Held
39.8KPut Options Held
6.1K-
Vanguard Group Inc Valley Forge, PA364KShares$1.29 Million0.0% of portfolio
-
Cm Management, LLC185KShares$654,9000.57% of portfolio
-
New Edge Advisors, LLC New Orleans, LA137KShares$486,1760.0% of portfolio
-
Geode Capital Management, LLC Boston, MA87.4KShares$309,5190.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny84KShares$297,3600.0% of portfolio
About Lantern Pharma Inc.
- Ticker LTRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,830,900
- Market Cap $38.3M
- Description
- Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...